Big Pharma and Drug Discovery

 The previous two posts have described talks at the FiRe 2026 conference, held in the Qualcomm Institute facility at the University of California at San Diego, one of America's premier science research institutes.  Toward the end of the 2nd day, CEO Mark Anderson of Pattern Computer introduced an hour of Pattern talks by various folk, the first of which was Pattern's work with AI in Pharma, for which Mark's opening (04:00-05:45) was important.    https://vimeo.com/1093395045?share=copy

After Mark's opening, Dr. Ben Brown of Pattern gave a synopsis of LLM and AI evolution and accomplishment, along with difficulties that have been hard to overcome to date.  (05:45-12:10).  It then shifted to a segment that covered the Drug discovery efforts and results for Pattern Computer, with a discussion led by Ian Walker, of IMW Pharma Ltd in Cambridge, England.   See segment 12:10 to 17:27 below:   https://vimeo.com/1093395045?share=copy

The significant slide that outlined Walker's talk is shown here:   

Several key points were made.  First, most of the AI search results to date, for nearly all of Pharma, have yet to yield any significant drug combinations or any disease diagnostics.  Why Pattern?  One is tempted to say, "Simple.  It is due to the multi-dimensional nature of the Pattern Engine", but while true, that is a bit hard to appreciate.  But 27 dimensions (vs. the 3-D world we 'know' or the 4-D world with time included) is vastly hard to appreciate of even conjure, but in such a world, big data combinations of molecular structures for diseases, drugs, and organisms is able to be outlined and researched.   And that has been the basis of the Pattern discoveries that led to the drug combinations listed above.  

Walker acknowledges and honors all of this, but then goes on to outline at length what that means for pharma and the world, which must take into account the lengthy trials and production cycles, followed by the awareness and acceptance and distribution of such solutions.  Clearly a convoluted and complex path to success. 

But it all has to start with efficacy, and for that, the scientific papers are a linchpin, based on the science and the trials.  In this context, the recent announcement of a potent aide for pancreatic cancer (results published in the New England Journal of Medicene, May 31, 2026) occasioned a standing ovation by doctors attending the ASCO meeting.

Each of Pattern's 8 drug trials and 3 biomarker developments deal with similarly difficult cancers--the results will likely be transformative.